Advisory Alpha’s Protalix BioTherapeutics PLX Stock Holding History

Advisory Alpha’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-500	Closed	-$950	–	884
2019 Q3	$950	Buy	+500	New	+$1.49K	﹤0.01%	742
2019 Q2	–	Sell	-500	Closed	-$2K	–	502
2019 Q1	$2K	Buy	+500	New	+$2.25K	﹤0.01%	552

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MWPCG

Measured Wealth Private Client Group Portsmouth, New Hampshire $366M AUM 21.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Advisory Alpha's PLX Position: Q4 2019 in Review

Advisory Alpha sold out of Protalix BioTherapeutics (PLX) in Q4 2019, closing a stake of 500 shares — an estimated $950 sold.

Advisory Alpha first reported a position in PLX in Q1 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 15 funds tracked by Wall St. Rank hold PLX as of Q4 2019.

Advisory Alpha reported no remaining Protalix BioTherapeutics position as of Q4 2019 after selling out during the quarter.
Advisory Alpha sold 500 Protalix BioTherapeutics shares in Q4 2019, an estimated $950.
Advisory Alpha first reported a position in Protalix BioTherapeutics in Q1 2019 and held it in 2 quarters.
Advisory Alpha's Protalix BioTherapeutics position peaked at $2K in Q1 2019.
15 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2019.

Based on Advisory Alpha's 13F filing for Q4 2019, filed 14 Feb 2020.